These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 25987623)

  • 1. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
    Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an
    Jahanbakhsh S; Singh NB; Yim J; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
    Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
    [No Abstract]   [Full Text] [Related]  

  • 7. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J; Vidaillac C; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4329-34. PubMed ID: 20696880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an
    Kunz Coyne AJ; Bleick C; Stamper K; Kebriaei R; Bayer AS; Lehman SM; Rybak MJ
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0138823. PubMed ID: 38376187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation
    Kunz Coyne AJ; Stamper K; El Ghali A; Kebriaei R; Biswas B; Wilson M; Deschenes MV; Tran TT; Arias CA; Rybak MJ
    Microbiol Spectr; 2023 Aug; 11(4):e0034023. PubMed ID: 37338375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
    Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
    LaPlante KL; Woodmansee S
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Geriak M; Haddad F; Rizvi K; Rose W; Kullar R; LaPlante K; Yu M; Vasina L; Ouellette K; Zervos M; Nizet V; Sakoulas G
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.